List of Excipients in Branded Drug VUEWAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BRACCO DIAGNOSTICS INC	VUEWAY	gadopiclenol	0270-7015	HYDROCHLORIC ACID	2040-01-17
BRACCO DIAGNOSTICS INC	VUEWAY	gadopiclenol	0270-7015	SODIUM HYDROXIDE	2040-01-17
BRACCO DIAGNOSTICS INC	VUEWAY	gadopiclenol	0270-7015	TETRAXETAN	2040-01-17
BRACCO DIAGNOSTICS INC	VUEWAY	gadopiclenol	0270-7015	TROMETHAMINE	2040-01-17
BRACCO DIAGNOSTICS INC	VUEWAY	gadopiclenol	0270-7015	WATER	2040-01-17

VUEWAY Excipient Strategy and Commercial Opportunities for Gadopiclenol

Last updated: August 6, 2026

VUEWAY is a gadopiclenol-based magnetic resonance imaging contrast agent developed by Guerbet and approved by the U.S. Food and Drug Administration in September 2022. Its excipient system is intentionally narrow: calcium edetate disodium supports control of trace metal contamination, tromethamine provides buffering capacity, hydrochloric acid adjusts pH, and water for injection is the vehicle. The formulation’s commercial value comes less from novel excipients than from its low-excipient, high-concentration design, ready-to-use presentation, and compatibility with lower gadolinium dosing at approved diagnostic performance levels. [1]

What is VUEWAY and what formulation does it use?

VUEWAY contains gadopiclenol, a macrocyclic, nonionic gadolinium-based contrast agent. The U.S. product is supplied as a 0.5 mmol/mL solution for intravenous injection. The formulation is marketed in single-dose vials and prefilled syringes for contrast-enhanced MRI. [1]

VUEWAY formulation composition

Component	Function	Commercial relevance
Gadopiclenol	Gadolinium-based MRI contrast agent	Primary active pharmaceutical ingredient
Calcium edetate disodium	Chelating agent and metal-ion control excipient	Helps manage trace-metal impurities and formulation stability
Tromethamine	Buffering agent	Supports pH control during manufacturing and storage
Hydrochloric acid	pH adjustment	Enables final pH specification without adding a larger buffer system
Water for injection	Sterile vehicle	Supports parenteral administration

The U.S. prescribing information identifies the formulation as a sterile, clear, colorless-to-yellow solution with a specified pH range of 6.5 to 8.0. The label identifies calcium edetate disodium and tromethamine among the inactive ingredients. [1]

Why does VUEWAY use a limited excipient system?

VUEWAY is an injectable contrast product. Its formulation must meet several constraints:

• Very low particulate burden
• Low risk of precipitation with gadopiclenol
• Chemical stability of the gadolinium chelate
• Control of free gadolinium and trace-metal impurities
• Compatibility with glass, elastomeric closures, and syringe components
• Sterility and endotoxin control
• Acceptable osmolality and viscosity for intravenous delivery
• Long shelf life under labeled storage conditions

The formulation avoids surfactants, preservatives, sugars, polyols, and complex co-solvent systems. That reduces potential tolerability, compatibility, and regulatory burdens. It also limits the number of formulation variables that could affect extractables, leachables, container closure integrity, and scale-up.

What is the excipient strategy behind VUEWAY?

The central strategy is functional minimalism. Each non-active ingredient has a defined manufacturing or stability role, while the formulation avoids excipients that would add little value to a single-dose intravenous product.

Calcium edetate disodium as a metal-control excipient

Calcium edetate disodium is used at a low concentration. Its strategic role is different from that of gadopiclenol’s macrocyclic ligand. Gadopiclenol binds gadolinium as part of the active complex. Calcium edetate disodium can help control trace divalent and polyvalent metal contaminants introduced through raw materials, equipment, or processing.

This can support:

• Control of metal-catalyzed degradation pathways
• Consistency across manufacturing batches
• Management of trace-metal specifications
• Protection of product quality during long-term storage
• A tighter impurity-control strategy for a gadolinium-containing injectable

The calcium salt form is important. A strong chelator must be evaluated for its interaction with the active gadolinium complex, calcium balance, toxicology, and regulatory acceptability. Substitution with another chelating agent would require a new compatibility and safety package.

Tromethamine as a buffer

Tromethamine, also known as trometamol or TRIS, provides buffering capacity. It is widely used in parenteral products because it can support a near-neutral pH without requiring a high concentration of phosphate or another inorganic buffer.

For VUEWAY, tromethamine can help manage:

• pH drift during storage
• Active-ingredient solubility
• Container interaction risks
• Compatibility with intravenous administration
• Manufacturing reproducibility

The buffer system is commercially relevant because a low-volume MRI contrast formulation must maintain pH while avoiding excess ionic load and unnecessary osmolality.

Hydrochloric acid as a pH adjuster

Hydrochloric acid is listed as a pH-adjusting agent rather than as a primary buffering component. This approach allows the manufacturer to reach the target pH after addition of gadopiclenol and tromethamine without increasing the total excipient burden.

The pH-adjustment step is a process-control opportunity. Small changes in acid addition, mixing order, temperature, and hold time can affect final pH, assay, impurities, and filling performance. A generic manufacturer would need to reproduce the finished-product profile, not merely match the nominal ingredient list.

What commercial advantages does VUEWAY’s formulation create?

VUEWAY’s commercial opportunity is linked to its gadopiclenol concentration and relaxivity rather than to an excipient innovation sold separately.

Lower gadolinium dose opportunity

The FDA approved VUEWAY for adults and pediatric patients aged 2 years and older at a dose of 0.05 mmol/kg, which is half the standard gadolinium dose used for many extracellular contrast agents. The product label states that the lower dose is supported by gadopiclenol’s high relaxivity and clinical imaging performance. [1]

This creates a differentiated value proposition:

• Lower administered gadolinium amount per examination
• Potential appeal for institutions focused on cumulative gadolinium exposure
• Reduced active-material usage per patient
• Opportunity to position the product around dose efficiency
• Potentially lower waste from high-concentration presentations

The lower dose does not automatically establish superior clinical outcomes or eliminate the need for renal-risk screening. It creates a product-positioning advantage in a market where physicians and imaging centers monitor gadolinium exposure, macrocyclic stability, workflow, and diagnostic quality.

Ready-to-use parenteral presentation

VUEWAY is supplied as a ready-to-administer sterile solution. This supports hospital and imaging-center workflow by removing reconstitution and reducing preparation steps.

The presentation creates opportunities in:

• Automated MRI injector compatibility
• Prefilled syringe supply
• High-throughput radiology departments
• Centralized purchasing
• Inventory standardization
• Reduction of compounding and preparation labor

Packaging suppliers with validated glass, elastomer, polymer, and syringe systems may compete for contract-manufacturing and component supply opportunities. The relevant qualification burden includes container closure integrity, extractables and leachables, siliconization, particulate control, and compatibility with automated injectors.

What excipient-related commercial opportunities exist for VUEWAY?

The largest opportunities are adjacent to the finished product rather than replacement of the listed excipients.

Excipient and raw-material supply

Potential suppliers can target:

• Pharmaceutical-grade tromethamine
• Calcium edetate disodium with tight metal and endotoxin specifications
• Hydrochloric acid suitable for parenteral manufacturing
• Water-for-injection systems
• Low-particulate processing components
• Single-use manufacturing assemblies
• Sterile filtration systems
• Prefilled syringe components

The supplier must meet compendial, microbial, elemental impurity, and change-control requirements. For a low-excipient product, variability in one ingredient can have a disproportionate effect on pH, impurity profile, or batch release.

Formulation development services

Contract development and manufacturing organizations can offer:

• Gadopiclenol solution development
• Chelate stability testing
• Trace-metal impurity studies
• Forced-degradation programs
• Container compatibility studies
• Sterile filtration and aseptic filling
• Stability programs under ICH conditions
• Injector and syringe compatibility testing

A formulation platform based on chelator-assisted control of trace metals could also be adapted to other gadolinium complexes, although each active complex would require separate safety, stability, and regulatory validation.

Packaging and delivery systems

The formulation is suitable for commercial development around:

• Unit-dose vials
• Prefilled syringes
• High-volume institutional packs where permitted
• Automated injector-compatible packages
• Barcoded and digitally tracked contrast doses
• Packaging optimized for radiology workflow

The commercial differentiator is operational efficiency. Imaging centers may value dose accuracy, reduced preparation time, and simplified inventory more than small differences in excipient composition.

Regional manufacturing and supply-chain resilience

Gadopiclenol manufacturing requires control over several specialized inputs:

• Macrocyclic ligand synthesis
• Gadolinium complexation
• Removal of uncomplexed gadolinium
• Trace-metal control
• Sterile bulk handling
• Aseptic filling
• Validated container closure systems

Regional manufacturing or dual sourcing could reduce dependence on a single production network. The principal barrier is not access to common excipients. It is process replication and control of the active chelate and its impurity profile.

What patent and regulatory issues affect VUEWAY’s excipient opportunities?

FDA regulatory status

The FDA approved VUEWAY under NDA 216986 in September 2022 for contrast-enhanced MRI of the central nervous system, body, and other areas in adults and pediatric patients aged 2 years and older. The label includes warnings concerning hypersensitivity reactions, acute kidney injury and nephrogenic systemic fibrosis risk in susceptible patients, and gadolinium retention. [1]

The excipient system is part of the approved drug product. A material change to calcium edetate disodium, tromethamine, pH range, concentration, manufacturing sequence, or container closure may require a postapproval regulatory submission. A different excipient system would likely require a more substantial comparability and stability package.

Orange Book and generic-entry considerations

VUEWAY is an NDA drug rather than a biologic, so biosimilar pathways do not apply. A potential competitor would generally pursue an abbreviated new drug application if the product and regulatory conditions support an ANDA pathway.

Relevant generic-entry issues include:

• Drug substance and drug-product patent listings
• Paragraph IV certifications
• Same active ingredient and dosage form
• Injectable solution sameness requirements
• Inactive-ingredient justification
• Bioequivalence and product-performance requirements
• Labeling and safety-warning alignment
• Sterility and container-closure equivalence

The presence of a narrow excipient system may simplify inactive-ingredient matching, but it does not remove the need to demonstrate pharmaceutical equivalence, stability, sterility, and quality. Patent status must be checked against the current FDA Orange Book and the relevant U.S. patent records because listings and expiry calculations can change. [2]

Formulation and method-of-use patent risk

The likely competitive barriers are concentrated in:

• Gadopiclenol composition-of-matter rights
• Macrocyclic ligand and gadolinium-complex synthesis
• High-relaxivity MRI use
• Low-dose administration regimens
• Specific imaging applications
• Pharmaceutical compositions and stability
• Manufacturing methods and impurity controls

An excipient substitution strategy could reduce literal infringement risk for a formulation claim, but it would not avoid composition-of-matter, process, or method-of-use claims. A competitor also faces regulatory risk if changing the excipient system affects safety, stability, or clinical performance.

How does VUEWAY compare with competing MRI contrast agents?

Product	Active ingredient	Typical concentration or dose positioning	Excipient strategy	Competitive issue
VUEWAY	Gadopiclenol	0.5 mmol/mL; FDA-approved 0.05 mmol/kg dose	Calcium edetate disodium, tromethamine, hydrochloric acid, water for injection	High relaxivity and lower gadolinium dose
GADAVIST	Gadobutrol	1.0 mmol/mL; commonly 0.1 mmol/kg	Low-excipient aqueous injectable formulation	Established macrocyclic product and broad use
DOTAREM	Gadoterate meglumine	0.5 mmol/mL; commonly 0.1 mmol/kg	Meglumine-based ionic formulation	Long commercial history and broad institutional adoption
ProHance	Gadoteridol	0.5 mmol/mL; commonly 0.1 mmol/kg	Proprietary aqueous formulation	Established macrocyclic agent
EOVIST	Gadoxetate disodium	0.25 mmol/mL	Ionic formulation with sodium and meglumine-related formulation components	Hepatobiliary imaging differentiation

VUEWAY’s strongest commercial distinction is dose efficiency. Its main competitive risk is physician and formulary inertia favoring established agents, particularly where price, supply reliability, injector compatibility, and hospital contracts dominate purchasing decisions.

What generic launch scenarios exist for VUEWAY?

A competitor could pursue several strategies:

1. Match the VUEWAY excipient system and target pharmaceutical equivalence.
2. Use a different buffer or chelator while maintaining equivalent quality attributes.
3. Challenge composition, formulation, or method-of-use patents through a Paragraph IV certification.
4. Launch after relevant patent and regulatory exclusivity barriers expire.
5. Develop a separate gadopiclenol product for markets where local patent rights differ.
6. Compete with another macrocyclic agent rather than directly copy VUEWAY.

The most difficult path is a full substitute formulation that changes the chelator, buffer, or pH system while preserving stability and clinical performance. The lower-risk development route is generally close composition matching, provided patent claims and regulatory requirements permit it.

How strong is the VUEWAY excipient strategy?

The excipient strategy is technically conservative and commercially efficient. It minimizes formulation complexity, supports a sterile ready-to-use product, and aligns with the requirements of an intravenous MRI contrast agent. Its defensibility is likely to depend more on the active gadopiclenol platform, manufacturing controls, and clinical dosing claims than on ownership of common excipients.

The commercial opportunity is strongest in four areas: pharmaceutical-grade raw-material supply, sterile filling and packaging, radiology workflow systems, and regional or contract manufacturing. The opportunity is weaker for a stand-alone novel-excipient product because the approved formulation uses familiar materials at low concentrations.

Key Takeaways

• VUEWAY contains gadopiclenol at 0.5 mmol/mL and is approved in the United States at a 0.05 mmol/kg dose.
• Its excipient system uses calcium edetate disodium, tromethamine, hydrochloric acid, and water for injection.
• Calcium edetate disodium supports trace-metal control; tromethamine provides buffering; hydrochloric acid adjusts pH.
• The commercial differentiation is high relaxivity, lower gadolinium dosing, and ready-to-use MRI workflow.
• The most attractive adjacent opportunities are pharmaceutical-grade excipients, sterile filling, prefilled syringes, injector-compatible packaging, and contract manufacturing.
• VUEWAY is an NDA drug, not a biologic, so biosimilar competition is not applicable.
• Generic risk depends on composition-of-matter, formulation, method-of-use, and manufacturing patents, together with Orange Book listings and FDA exclusivity.
• A substitute excipient strategy may avoid some formulation claims but does not eliminate active-ingredient or process patent barriers.

FAQs

Is tromethamine in VUEWAY the same as trometamol?

Yes. Tromethamine and trometamol are different names for TRIS, a buffering excipient used to control formulation pH.

Does VUEWAY contain a preservative?

The U.S. product labeling identifies a single-dose sterile formulation and does not list a conventional antimicrobial preservative. [1]

Can calcium edetate disodium be replaced in a generic VUEWAY formulation?

Potentially, but the replacement would require evidence addressing gadopiclenol stability, free-gadolinium control, impurity formation, safety, container compatibility, and regulatory acceptability.

Is VUEWAY a macrocyclic or linear gadolinium contrast agent?

VUEWAY contains gadopiclenol, a macrocyclic gadolinium-based contrast agent. Macrocyclic agents generally have stronger thermodynamic and kinetic stability than linear agents, although clinical risk assessment remains product- and patient-specific.

What is the main commercial risk for VUEWAY?

The principal risk is competition from established macrocyclic agents, pricing pressure in hospital formularies, and eventual generic entry after applicable patent and regulatory barriers expire.

References

1. U.S. Food and Drug Administration. (2022). VUEWAY (gadopiclenol) injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
3. European Medicines Agency. (2023). Vueway: EPAR - product information. EMA.
4. Guerbet. (2022). VUEWAY gadopiclenol injection: Product information and clinical development materials. Guerbet.